277. The Rounds Table- Top Papers from the 2025 American College of Cardiology (ACC) Session

In a rapid-fire session, experts discuss groundbreaking findings from the 2025 American College of Cardiology conference. They dive into the efficacy of reduced-dose apixaban for cancer-related blood clots, highlighting its potential advantages. The DAPA-TAVI trial sheds light on the promising role of SGLT2 inhibitors in heart failure management. Additionally, the cardiovascular benefits of oral semaglutide in high-risk diabetes patients are explored, revealing significant reductions in adverse events. A sprinkle of humor is added with a mention of a new comedy series.